jmbowen70 asked
I have been taken Breo and now my new doctor has changed me to Trelegy. What I want to know is if the side effects are the same for both inhalers?
At a glance
- Breo and Trelegy share similar side effects since they share two of the same active ingredients. The anticholinergic in Trelegy, umeclidinium, can additionally cause gastrointestinal side effects (e.g. diarrhea) as well as dry mouth and dry eyes.
- Breo is used for asthma and COPD while Trelegy is a second-line option for COPD only.
Answer
There are several FDA-approved inhalers for the maintenance and treatment of COPD (chronic obstructive pulmonary disease). Two of the most commonly prescribed are:
- Breo Ellipta
- Trelegy Ellipta
Below, I detail the differences between them (including the side effects which you are concerned about).
Breo Vs. Trelegy: Active Ingredients
The main difference between Breo and Trelegy are the active ingredients in both.
Breo contains:
Trelegy contains:
- Vilanterol
- Fluticasone furoate
- Umeclidinium
As you can see, Breo and Trelegy share two of the same active ingredients (vilanterol and fluticasone furoate) but Trelegy contains one additional, umeclidinium. All of these active ingredients are discussed below.
Vilanterol
Vilanterol is classified as a long-acting beta-2 adrenergic agonist, or LABA, for short.
It acts on 'beta-2 receptors' in the lungs, which causes the relaxation of smooth muscle in the airways. This relaxation results in increased airflow. Vilanterol acts on the same receptors as albuterol, but is much longer lasting, which is why it is classified as a 'LABA'. Albuterol is known as a SABA (short-acting beta-agonist).
Vilanterol is in both Breo and Trelegy.
Fluticasone Furoate
Fluticasone furoate is a corticosteroid, which acts on many different cells involved in inflammatory pathways. Cells it acts on include:
- Mast cells
- Eosinophils
- Neutrophils
- Macrophages
- Lymphocytes
Corticosteroids also act on inflammatory mediators, such as histamine and leukotrienes.
Fluticasone furoate is similar to fluticasone propionate (the active ingredient in Flovent), but binds more strongly to corticosteroid receptors.
Vilanterol is in both Breo and Trelegy.
Umeclidinium
Umeclidinium is an anticholinergic. It not only causes dilation of the muscles of the airways (i.e. bronchodilation) but also helps to dry mucous and saliva secretions. The overall result is increased airflow.
Anticholinergics are often used for the treatment of COPD. Aside from umeclidinium, Spiriva (tiotropium) is another commonly used anticholinergic.
Breo Vs. Trelegy: Use
Breo is FDA-approved for the treatment of asthma and is a first-line recommended treatment for COPD.
Trelegy, on the other hand, is only FDA approved for the treatment of COPD, but only as a second-line option according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines.
The GOLD guidelines recommend that 'triple combination products', like Trelegy should be reserved for those who have already tried a two-ingredient product, like Breo. Studies referenced in the GOLD guidelines state that, in these particular individuals, triple combination therapy improves lung function and associated symptoms.
References
- Elsevier ClinicalKey: Breo Monograph (Accessed 2/22/19)
- Elsevier ClinicalKey: Trelegy Monograph (Accessed 2/22/19)
- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. PubMed
- Breo Prescribing Information
- Trelegy Prescribing Information